These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 862343)
41. Action of 1alpha-hydroxy vitamin D3 on calcium absorption and bone resorption in man. Peacock M; Gallagher JC; Nordin BE Lancet; 1974 Mar; 1(7854):385-89. PubMed ID: 4131034 [No Abstract] [Full Text] [Related]
42. Osteomalacia and insufficiency fracture in a hemodialysis patient with autosomal dominant polycystic kidney disease. Hiramatsu R; Ubara Y; Suwabe T; Sumida K; Hayami N; Yamanouchi M; Mise K; Hasegawa E; Hoshino J; Sawa N; Takaichi K Intern Med; 2012; 51(23):3277-80. PubMed ID: 23207124 [TBL] [Abstract][Full Text] [Related]
43. Dose-dependent effects of strontium on bone of chronic renal failure rats. Schrooten I; Behets GJ; Cabrera WE; Vercauteren SR; Lamberts LV; Verberckmoes SC; Bervoets AJ; Dams G; Goodman WG; De Broe ME; D'Haese PC Kidney Int; 2003 Mar; 63(3):927-35. PubMed ID: 12631073 [TBL] [Abstract][Full Text] [Related]
44. Preliminary trials with 24,25-dihydroxyvitamin D3 in dialysis osteomalacia. Hodsman AB; Wong EG; Sherrard DJ; Brickman AS; Lee DB; Singer FR; Norman AW; Coburn JW Am J Med; 1983 Mar; 74(3):407-14. PubMed ID: 6338716 [TBL] [Abstract][Full Text] [Related]
45. Renal osteodystrophy in dialysis patients: diagnosis and treatment. Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690 [TBL] [Abstract][Full Text] [Related]
46. Curative effects of 1alpha-hydroxycholecalciferol on calcium metabolism and bone disease in patients with chronic renal failure. Hirooka M; Wako H; Kaneko C; Ishikawa M; Sasaki S J Nutr Sci Vitaminol (Tokyo); 1975; 21(4):277-85. PubMed ID: 1214180 [TBL] [Abstract][Full Text] [Related]
47. [Treatment with 1-alpha hydroxy vitamin D3 of bone disease in hemodialysis. Therapeutic results and complications]. García de Vinuesa S; Barril G; Luño J; Alles A; Jofré R; Pérez García R; Olivas E; López Gómez JM; Valderrábano F Rev Clin Esp; 1980 Dec; 159(5):317-22. PubMed ID: 7221095 [No Abstract] [Full Text] [Related]
48. The action of 1alphahydroxy vitamin D3 and phosphate supplements in hypophosphataemic osteomalacia. Peacock M; Aaron JE; Heyburn PJ; Nordin BE Adv Exp Med Biol; 1977; 81():431-40. PubMed ID: 899935 [No Abstract] [Full Text] [Related]
50. [Comparative clinical and histomorphological studies on the therapy of renal osteopathy using vitamin D and 5,6-trans-25-OHCC]. Schulz W; Heidler R; Gessler U; Offermann G; Schulz A; Delling G Verh Dtsch Ges Inn Med; 1975; 81():976-80. PubMed ID: 1229631 [No Abstract] [Full Text] [Related]
51. Skeletal response to treatment with 1,25-dihydroxyvitamin D in renal failure. Sherrard DJ; Coburn JW; Brickman AS; Singer FR; Maloney N Contrib Nephrol; 1980; 18():92-7. PubMed ID: 7353382 [No Abstract] [Full Text] [Related]
52. Role of 1,25-dihydroxyvitamin D3 in maintaining serum phosphorus and curing rickets. Tanaka Y; Deluca HF Proc Natl Acad Sci U S A; 1974 Apr; 71(4):1040-4. PubMed ID: 4524612 [TBL] [Abstract][Full Text] [Related]
53. Long-term effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy. Ahmed KY; Varghese Z; Wills MR; Meinhard EA; Moorhead JF Lancet; 1978 Mar; 1(8065):629-32. PubMed ID: 76168 [TBL] [Abstract][Full Text] [Related]
54. An evaluation of 1 alpha-hydroxy-and 1,25-dihydroxyvitamin D3 in the treatment of renal bone disease. Kanis JA; Russell RG; Cundy T; Earnshaw M; Woods CG; Smith R; Heynen G Contrib Nephrol; 1980; 18():12-28. PubMed ID: 7353370 [TBL] [Abstract][Full Text] [Related]
56. Failure of formation of 1,25-dihydroxycholecalciferol in chronic renal insufficiency. Mawer EB; Taylor CM; Backhouse J; Lumb GA; Stanbury SW Lancet; 1973 Mar; 1(7804):626-8. PubMed ID: 4121843 [No Abstract] [Full Text] [Related]
57. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination. Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862 [TBL] [Abstract][Full Text] [Related]
58. The action of 1,25 (OH)2D3 on turnover kinetic, remodelling surfaces and structure of trabecular bone in chronic renal failure. Delling G; Lühmann H; Bulla M; Fuchs C; Henning HV; Jansen JL; Kohnle W; Schulz W Contrib Nephrol; 1980; 18():105-21. PubMed ID: 7353369 [TBL] [Abstract][Full Text] [Related]
59. Proceedings: The use of metabolically-active derivatives of vitamin D in rickets and osteomalacia due to renal glomerular failure. Smith R; Henderson RG; Russell RG J Bone Joint Surg Br; 1975 May; 57(2):247-8. PubMed ID: 1141297 [No Abstract] [Full Text] [Related]
60. Effect of 25-hydroxy-vitamin D3 on intestinal absorption of calcium in normal man and patients with renal failure. Colodro IH; Brickman AS; Coburn JW; Osborn TW; Norman AW Metabolism; 1978 Jun; 27(6):745-53. PubMed ID: 651659 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]